Please assess the completion status of the following clinical trial:

Trial Title: ETEC Logistics Trial (TREK)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult men and women 18-64 years of age inclusive at screening~* Signed Informed Consent form~* Planned travel to an area within 2 ½ hours traveling distance of Cuernavaca or Guadalajara, Mexico or Antigua, Guatemala (minimum stay of 7 days)~* If female who is not post-menopausal or surgically sterile, negative pregnancy test (within 24 hours prior to vaccination) and agreement to employ an effective form of birth control or practice abstinence through the end of the study.~Exclusion Criteria:~* Clinically significant abnormalities as determined by the Investigator/clinician during physical inspection~* Received investigational product from 30 days before date of first vaccination or during the entire study period~* Ever received LT, ETEC, or cholera vaccine~* History of traveler's diarrhea within the previous year~* Travel to a developing country within the last year~* Women who are pregnant or breastfeeding~* History of achlorhydria~* Evidence of immunosuppression, including concomitant immunosuppressive therapy; fever \> 99.5°F (37.5°C) on day of vaccination~* Current problems with alcohol or substance abuse~* An employee of the study clinic~* Sensitivity or allergy to any of the vaccine components~* History of significant blood loss, blood product donation, or blood product recipient in the previous 60 days~* Planned use of Imodium or antibiotics for self treatment of diarrhea during the study period~* Visible tattoos or marks (tattoos/scars) at the vaccination areas that would prevent appropriate dermatologic monitoring of the vaccination sites; and~* Medical history of acute or chronic GI illness or major GI surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
- Group 2 (Type: PLACEBO_COMPARATOR): Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)

Based on this trial design, predict the completion outcome and termination type (if applicable).